Brind.

FDA is adjusting drug review strategies, showing openness to less data, while China surpasses the U.S. in drug research.

Steady: 0 in the last 7 days Updated oct 7

The latest in this situation

  1. FDA data failed to support accelerated clearance as China gains market share over Europe.
  2. Innovent Biologics commercializes mazdutide for OPKO's license.

How it started

4 reports, 4 independent, last reported Tue 00:00. The briefing below covers this first event.

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Well supportedReported by 4 independent outlets

FDA is adjusting drug review strategies, showing openness to less data, while China surpasses the U.S. in drug research.

Who's involved

What this event is mainly about
Innovent BiologicsFDAEli Lilly and Company

How it developed

Newest first. Tap a step to see who reported it.
  1. FDA data failed to support accelerated clearance as China gains market share over Europe.1 source
  2. Innovent Biologics commercializes mazdutide for OPKO's license.Sub-event
  3. An experimental drug, sourced from China, is under FDA scrutiny after marketing claims of being 'the ultimate good' and subsequent warnings were issued.Sub-event
  4. FDA shifts regulatory approach and China overtakes the U.S. in drug research.1 source

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped